

PF 42(4) Table of Contents

Publish date: June 28, 2016

PROPOSED IRA

[Proposed Interim Revision Announcements](#)

USP MONOGRAPHS

[Acitretin Capsules \(1-Jan-2017\)](#)

[Aspirin Boluses \(1-Jan-2017\)](#)

[Aspirin Delayed-Release Capsules \(1-Jan-2017\)](#)

[Aspirin Tablets \(1-Jan-2017\)](#)

[Buffered Aspirin Tablets \(1-Jan-2017\)](#)

[Aspirin Delayed-Release Tablets \(1-Jan-2017\)](#)

[Aspirin Effervescent Tablets for Oral Solution \(1-Jan-2017\)](#)

[Aspirin Extended-Release Tablets \(1-Jan-2017\)](#)

[Aspirin, Alumina, and Magnesia Tablets \(1-Jan-2017\)](#)

[Doxorubicin Hydrochloride Injection \(1-Jan-2017\)](#)

[Eprinomectin \(1-Jan-2017\)](#)

[Naproxen Sodium Tablets \(1-Jan-2017\)](#)

NF MONOGRAPHS

[Octyldodecanol \(1-Jan-2017\)](#)

IN-PROCESS REVISION

[In-Process Revisions](#)

GENERAL CHAPTERS

[<91> CALCIUM PANTOTHENATE ASSAY \(USP40-NF35 2S\)](#)

[<115> DEXPANTHENOL ASSAY \(USP40-NF35 2S\)](#)

[<661.1> PLASTIC MATERIALS OF CONSTRUCTION \(USP40-NF35 2S\)](#)

[<661.2> PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE \(USP40-NF35 2S\)](#)

[<771> OPHTHALMIC PRODUCTS-QUALITY TESTS \(USP40-NF35 2S\)](#)

[<781> OPTICAL ROTATION \(USP40-NF35 2S\)](#)

[<785> OSMOLALITY AND OSMOLARITY \(USP40-NF35 2S\)](#)

[<857> ULTRAVIOLET-VISIBLE SPECTROSCOPY \(USP40-NF35 2S\)](#)

[<1079.1> STORAGE AND TRANSPORTATION OF INVESTIGATIONAL DRUG PRODUCTS \[NEW\] \(USP40-NF35 2S\)](#)

[<1090> ASSESSMENT OF DRUG PRODUCT PERFORMANCE BIOAVAILABILITY, BIOEQUIVALENCE, AND DISSOLUTION \(USP40-NF35 2S\)](#)

[<1857> ULTRAVIOLET-VISIBLE SPECTROSCOPY—THEORY AND PRACTICE \(USP40-NF35 2S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[Benzil \[NEW\] \(USP40-NF35 2S\)](#)
[Butylparaben \[NEW\] \(USP40-NF35 2S\)](#)
[Desoxycorticosterone Acetate \[NEW\] \(USP40-NF35 2S\)](#)
[Linolenic Acid \[NEW\] \(USP40-NF35 2S\)](#)
[\(R\)-\(-\)-Littorine Hydrochloride \[NEW\] \(USP40-NF35 2S\)](#)
[p-Methoxyacetophenone \[NEW\] \(USP40-NF35 2S\)](#)
[Polyvinyl Alcohol \(USP40-NF35 2S\)](#)
[Undecanoic Acid \[NEW\] \(USP40-NF35 2S\)](#)

Test Solutions

[0.125 N Hydrochloric Acid TS \[NEW\] \(USP40-NF35 2S\)](#)
[1.5 M Phosphoric Acid TS \[NEW\] \(USP40-NF35 2S\)](#)
[0.1% Trifluoroacetic Acid TS \[NEW\] \(USP40-NF35 2S\)](#)

Volumetric Solutions

[0.05 M Barium Perchlorate VS \[NEW\] \(USP40-NF35 2S\)](#)

Chromatographic Columns

[L102 \(USP40-NF35 2S\)](#)

REFERENCE TABLES

Container Specifications

[Container Specifications \[NEW\] \(USP40-NF35 2S\)](#)

Description and Solubility

[Description and Relative Solubility of USP and NF Articles \(USP40-NF35 2S\)](#)
[Description and Solubility - B](#)
[Description and Solubility - F](#)
[Description and Solubility - G](#)

USP MONOGRAPHS

[Acetaminophen, Guaifenesin, Dextromethorphan Hydrobromide, and Phenylephrine Hydrochloride Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Acetaminophen, Guaifenesin, and Phenylephrine Hydrochloride Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Acetaminophen, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Dextromethorphan Hydrobromide Oral Suspension \[NEW\] \(USP40-NF35 2S\)](#)
[Atropine Sulfate Injection \(USP40-NF35 2S\)](#)
[Atropine Sulfate Ophthalmic Ointment \(USP40-NF35 2S\)](#)
[Atropine Sulfate Ophthalmic Solution \(USP40-NF35 2S\)](#)

[Bimatoprost \[NEW\] \(USP40-NF35 2S\)](#)
[Bimatoprost Ophthalmic Solution \[NEW\] \(USP40-NF35 2S\)](#)
[Brimonidine Tartrate \[NEW\] \(USP40-NF35 2S\)](#)
[Cinacalcet Hydrochloride \[NEW\] \(USP40-NF35 2S\)](#)
[Cinacalcet Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Cinoxacin \(USP40-NF35 2S\)](#)
[Cinoxacin Capsules \(USP40-NF35 2S\)](#)
[Cyclophosphamide Tablets \(USP40-NF35 2S\)](#)
[Desoxycorticosterone Acetate \(USP40-NF35 2S\)](#)
[Desoxycorticosterone Acetate Injection \(USP40-NF35 2S\)](#)
[Desoxycorticosterone Acetate Pellets \(USP40-NF35 2S\)](#)
[Dexamethasone \(USP40-NF35 2S\)](#)
[Dexmedetomidine Injection \[NEW\] \(USP40-NF35 2S\)](#)
[Diclofenac Potassium \(USP40-NF35 2S\)](#)
[Diclofenac Sodium \(USP40-NF35 2S\)](#)
[Dienestrol \(USP40-NF35 2S\)](#)
[Dienestrol Cream \(USP40-NF35 2S\)](#)
[Doxycycline Calcium Oral Suspension \(USP40-NF35 2S\)](#)
[Doxycycline Hyclate Delayed-Release Tablets \(USP40-NF35 2S\)](#)
[Eptifibatide \[NEW\] \(USP40-NF35 2S\)](#)
[Famciclovir Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Fingolimod Hydrochloride \[NEW\] \(USP40-NF35 2S\)](#)
[Fluvastatin Sodium Extended-Release Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Guanidine Hydrochloride \[NEW\] \(USP40-NF35 2S\)](#)
[Hypromellose Capsule Shell \[NEW\] \(USP40-NF35 2S\)](#)
[Linezolid \[NEW\] \(USP40-NF35 2S\)](#)
[Lorazepam \(USP40-NF35 2S\)](#)
[Metoprolol Tartrate and Hydrochlorothiazide Tablets \(USP40-NF35 2S\)](#)
[Nandrolone Phenpropionate \(USP40-NF35 2S\)](#)
[Nandrolone Phenpropionate Injection \(USP40-NF35 2S\)](#)
[Naproxen \(USP40-NF35 2S\)](#)
[Naproxen Oral Suspension \(USP40-NF35 2S\)](#)
[Naproxen Delayed-Release Tablets \(USP40-NF35 2S\)](#)
[Naproxen Sodium \(USP40-NF35 2S\)](#)
[Oxaprozin \(USP40-NF35 2S\)](#)
[Paraldehyde \(USP40-NF35 2S\)](#)
[Pioglitazone and Metformin Hydrochloride Tablets \(USP40-NF35 2S\)](#)
[Pramipexole Dihydrochloride \(USP40-NF35 2S\)](#)
[Reserpine Injection \(USP40-NF35 2S\)](#)
[Reserpine Oral Solution \(USP40-NF35 2S\)](#)
[Reserpine and Hydrochlorothiazide Tablets \(USP40-NF35 2S\)](#)
[Riluzole Tablets \(USP40-NF35 2S\)](#)
[Sodium Acetate \(USP40-NF35 2S\)](#)
[Sulfamethoxazole \(USP40-NF35 2S\)](#)

[Telmisartan and Amlodipine Tablets \[NEW\] \(USP40-NF35 2S\)](#)
[Terbinafine Tablets \(USP40-NF35 2S\)](#)
[Trandolapril and Verapamil Hydrochloride Extended-Release Tablets \(USP40-NF35 2S\)](#)
[Tranylcypromine Tablets \(USP40-NF35 2S\)](#)
[Triacetin \(USP40-NF35 2S\)](#)
[Zolpidem Tartrate Tablets \(USP40-NF35 2S\)](#)
[Zonisamide Capsules \(USP40-NF35 2S\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Conjugated Linoleic Acids–Free Fatty Acids \[NEW\] \(USP40-NF35 2S\)](#)
[Conjugated Linoleic Acids–Triglycerides \[NEW\] \(USP40-NF35 2S\)](#)
[Rhodiola crenulata Root and Rhizome \[NEW\] \(USP40-NF35 2S\)](#)
[Rhodiola crenulata Root and Rhizome Dry Extract \[NEW\] \(USP40-NF35 2S\)](#)
[Rhodiola crenulata Root and Rhizome Powder \[NEW\] \(USP40-NF35 2S\)](#)

NF MONOGRAPHS

[Octyldodecanol \(USP40-NF35 2S\)](#)

EXCIPIENTS

USP and NF Excipients, Listed By Category (USP40-NF35 2S)

[Briefing](#)

[Introduction](#)

[Chaotropic Agent](#)

STAGE 4 HARMONIZATION

[Stage 4 Harmonization](#)

STIMULI TO THE REVISION PROCESS

[STIMULI TO THE REVISION PROCESS](#)

[The Effect of Primary Packaging on the Physical Degradation of Metformin, Lisinopril, and Simvastatin Solid Doses During Patient Use When Stored at Different Temperature and Humidity Conditions](#)

[Future of Element-Specific Chapters in the USP–NF](#)

[Rationale for the Omission of the Packaging and Storage Statement from USP–NF Monographs and the Omission of the “Well-Closed” Specification from Containers—Performance Testing <671>](#)